Evidence map›Paper›PMID 40767389›Full record

ArticleEuropean journal of heart failure2025

Clinical and echocardiographic phenotype of cardiac wasting in patients with advanced cancer.

Markus S Anker, Muhammad Shahzeb Khan, Anja Nikolski, Jan Porthun, Muhammad Sameer Arshad, Sara Hadzibegovic, Alessia Lena, Lucie Kretzler, Jonathan L Hella, Marco Witkowski and 18 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in European journal of heart failure, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. What's new in heart failure? November 2025.European journal of heart failure · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

28 authors.

Markus S AnkerCharité - University Medicine Berlin corporate member of Free University Berlin and Humboldt-University Berlin, Berlin, Germany.ORCID https://orcid.org/0000-0002-4406-8555
Muhammad Shahzeb KhanBaylor Scott and White Heart Hospital, Plano, Texas, USA.
Anja NikolskiCharité - University Medicine Berlin corporate member of Free University Berlin and Humboldt-University Berlin, Berlin, Germany.
Jan PorthunCharité - University Medicine Berlin corporate member of Free University Berlin and Humboldt-University Berlin, Berlin, Germany.
Muhammad Sameer ArshadDow University of Health Sciences, Karachi, Pakistan.
Sara HadzibegovicCharité - University Medicine Berlin corporate member of Free University Berlin and Humboldt-University Berlin, Berlin, Germany.
Alessia LenaCharité - University Medicine Berlin corporate member of Free University Berlin and Humboldt-University Berlin, Berlin, Germany.
Lucie KretzlerCharité - University Medicine Berlin corporate member of Free University Berlin and Humboldt-University Berlin, Berlin, Germany.
Jonathan L HellaCharité - University Medicine Berlin corporate member of Free University Berlin and Humboldt-University Berlin, Berlin, Germany.
Marco WitkowskiCharité - University Medicine Berlin corporate member of Free University Berlin and Humboldt-University Berlin, Berlin, Germany.
Kathrin RiegerDepartment of Hematology, Oncology and Cancer Immunology, Charité - University Medicine Berlin corporate member of Free University Berlin and Humboldt University Berlin, Berlin, Germany.
Johann AhnDepartment of Hematology, Oncology and Cancer Immunology, Charité - University Medicine Berlin corporate member of Free University Berlin and Humboldt University Berlin, Berlin, Germany.
Dominik P ModestDepartment of Hematology, Oncology and Cancer Immunology, Charité - University Medicine Berlin corporate member of Free University Berlin and Humboldt University Berlin, Berlin, Germany.
Ulrich KellerDepartment of Hematology, Oncology and Cancer Immunology, Charité - University Medicine Berlin corporate member of Free University Berlin and Humboldt University Berlin, Berlin, Germany.
Lars BullingerDepartment of Hematology, Oncology and Cancer Immunology, Charité - University Medicine Berlin corporate member of Free University Berlin and Humboldt University Berlin, Berlin, Germany.
Matthias TotzeckNational Center for Tumor Diseases (NCT), partner site Berlin, and German Cancer Research Center (DKFZ), Heidelberg, Germany.
Amir A MahabadiDepartment of Cardiology and Vascular Medicine, West German Heart and Vascular Center, University Hospital Essen, Essen, Germany.
Tienush RassafDepartment of Cardiology and Vascular Medicine, West German Heart and Vascular Center, University Hospital Essen, Essen, Germany.
Nikolaus BuchmannCharité - University Medicine Berlin corporate member of Free University Berlin and Humboldt-University Berlin, Berlin, Germany.
Philipp AttanasioCharité - University Medicine Berlin corporate member of Free University Berlin and Humboldt-University Berlin, Berlin, Germany.
Tanja ZellerGerman Center for Cardiovascular Research (DZHK e.V.) partner site Hamburg/Lübeck/Kiel, Hamburg, Germany.
Mahir KarakasGerman Center for Cardiovascular Research (DZHK e.V.) partner site Hamburg/Lübeck/Kiel, Hamburg, Germany.
Carlo G TocchettiCardio-Pulmonary Onco-Immunology, Department of Internal Medicine and Clinical Complexity, Department of Translational Medical Sciences (DISMET), Federico II University, Naples, Italy.
Ursula WilkenshoffCharité - University Medicine Berlin corporate member of Free University Berlin and Humboldt-University Berlin, Berlin, Germany.
John G F ClelandSchool of Cardiovascular and Metabolic Health, University of Glasgow, Glasgow, UK.
Stephan von HaehlingDepartment of Cardiology and Pneumology, University of Göttingen Medical Center, Göttingen, Germany.
Javed Butler *Baylor Scott and White Research Institute, Dallas, TX, USA.
Ulf Landmesser *Charité - University Medicine Berlin corporate member of Free University Berlin and Humboldt-University Berlin, Berlin, Germany.

Funding

German Centre for Cardiovascular Research
6 · The paper itself

Abstract

aimsCardiac wasting-associated cardiomyopathy in patients with advanced cancer is characterized by loss of left ventricular (LV) mass and independently associated with poor prognosis. Better understanding of this very prevalent cardiomyopathy is urgently needed. METHODS AND

resultsOverall, 398 patients with active, mostly advanced cancer without significant cardiovascular disease (mean LV ejection fraction [LVEF] 64.3 ± 0.2%) or active infection were prospectively examined (mean age 60 ± 1 years, 50% women, body mass index 25.0 ± 0.2 kg/m

conclusionsPatients with advanced cancer with low LV mass have a distinct phenotype characterized by lower cardiac chamber volumes, stroke volume, and cardiac output, but normal LVEF and GLS that may be the distinct feature of cardiac wasting-associated cardiomyopathy.

Indexed as

CachexiaCardiomyopathiesHeart VentriclesNeoplasmsVentricular Function, LeftAgedEchocardiographyFemaleHumansMaleMiddle AgedPhenotypePrognosisProspective StudiesStroke VolumeCancerCardiac wasting cardiomyopathyEchocardiographyLeft ventricular massPathophysiology

Identifiers

PMID40767389
PMCPMC12765034

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.